association of a genetic risk score (GRS) composed of 47 susceptibility variants for coronary heart disease (CHD; GRS47) and a GRS composed of 32 variants (GRS32) with secondary CHD events, specifically acute coronary syndrome; a 153-variant GRS (GRS153) was not predictive. This is consistent with the association of a 27-variant GRS with the frequency of primary CHD events and clinical response to statin therapy 2 and a 30-variant GRS with the age of onset of incident CHD events.
Perhaps a multilocus GRS unique to CHD could be used for further studies to refine atherosclerotic cardiovascular disease risk and predict recurrence. The GRS would potentially be additive and independently improve the area under the curve for CHD risk prediction once variants related to CHD risk factors are removed. CHD prevention guidelines are continuously evolving, and incorporation of a GRS that enhances CHD risk prediction could be tremendously useful. Such a GRS may be of particular benefit to clinical decisionmaking for patients uncertain about initiating statin therapy, curious to know whether they will reap individualized substantial benefit, and who may need aggressive primordial, primary, or secondary prevention of CHD.
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